Market Closed -
Nasdaq
04:00:00 2024-05-24 pm EDT
|
5-day change
|
1st Jan Change
|
28.95
USD
|
+1.97%
|
|
-5.70%
|
-31.28%
|
Fiscal Period: March |
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Capitalization
1 |
850.7
|
1,571
|
641.3
|
2,005
|
4,206
|
-
|
-
|
Enterprise Value (EV)
1 |
850.7
|
1,171
|
147.5
|
1,628
|
3,554
|
3,675
|
3,918
|
P/E ratio
|
-10.1
x
|
-13.1
x
|
-3.85
x
|
-9.07
x
|
-16.2
x
|
-15.9
x
|
-14.7
x
|
Yield
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Capitalization / Revenue
|
-
|
-
|
-
|
-
|
-
|
292
x
|
80.3
x
|
EV / Revenue
|
-
|
-
|
-
|
-
|
-
|
255
x
|
74.8
x
|
EV / EBITDA
|
-
|
-10.8
x
|
-0.95
x
|
-7.47
x
|
-13.7
x
|
-14.2
x
|
-12.7
x
|
EV / FCF
|
-15.9
x
|
-14
x
|
-1.39
x
|
-8.64
x
|
-16.8
x
|
-13.1
x
|
-14.3
x
|
FCF Yield
|
-6.28%
|
-7.13%
|
-72.1%
|
-11.6%
|
-5.94%
|
-7.65%
|
-6.98%
|
Price to Book
|
-
|
3.6
x
|
1.29
x
|
5.58
x
|
6.42
x
|
10.3
x
|
26.9
x
|
Nbr of stocks (in thousands)
|
54,655
|
97,971
|
116,396
|
129,260
|
145,293
|
-
|
-
|
Reference price
2 |
15.56
|
16.04
|
5.510
|
15.51
|
28.95
|
28.95
|
28.95
|
Announcement Date
|
6/29/20
|
6/1/21
|
6/8/22
|
5/22/23
|
-
|
-
|
-
|
Fiscal Period: March |
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net sales
1 |
-
|
-
|
-
|
-
|
-
|
14.41
|
52.37
|
EBITDA
1 |
-
|
-108.1
|
-155.9
|
-218.1
|
-259.4
|
-259.5
|
-307.9
|
EBIT
1 |
-66.08
|
-108.1
|
-156
|
-218.3
|
-266.4
|
-291.2
|
-319.7
|
Operating Margin
|
-
|
-
|
-
|
-
|
-
|
-2,020.6%
|
-610.55%
|
Earnings before Tax (EBT)
1 |
-66.29
|
-107.8
|
-156.8
|
-211
|
-251.6
|
-300.5
|
-314.1
|
Net income
1 |
-66.39
|
-107.4
|
-156.7
|
-211
|
-249.6
|
-275.7
|
-313.2
|
Net margin
|
-
|
-
|
-
|
-
|
-
|
-1,912.79%
|
-598.18%
|
EPS
2 |
-1.540
|
-1.220
|
-1.430
|
-1.710
|
-1.787
|
-1.825
|
-1.976
|
Free Cash Flow
1 |
-53.39
|
-83.54
|
-106.4
|
-188.4
|
-211
|
-281.1
|
-273.7
|
FCF margin
|
-
|
-
|
-
|
-
|
-
|
-1,950.27%
|
-522.61%
|
FCF Conversion (EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
FCF Conversion (Net income)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Dividend per Share
2 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
6/29/20
|
6/1/21
|
6/8/22
|
5/22/23
|
-
|
-
|
-
|
Fiscal Period: March |
2022 Q2
|
2022 Q3
|
2022 Q4
|
2023 Q1
|
2023 Q2
|
2023 Q3
|
2023 Q4
|
2024 Q1
|
2024 Q2
|
2024 Q3
|
2024 Q4
|
2025 Q1
|
2025 Q2
|
2025 Q3
|
2025 Q4
|
---|
Net sales
1 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
EBITDA
1 |
-
|
-
|
-47.19
|
-40.33
|
-49.57
|
-63.98
|
-64.2
|
-78.42
|
-61.74
|
-61.44
|
-57.71
|
-
|
-
|
-
|
-
|
EBIT
1 |
-37.65
|
-41.27
|
-47.23
|
-40.38
|
-49.61
|
-64.03
|
-64.26
|
-78.48
|
-61.8
|
-61.55
|
-64.73
|
-68.85
|
-73.08
|
-75.83
|
-78.48
|
Operating Margin
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Earnings before Tax (EBT)
1 |
-37.73
|
-41.38
|
-47.18
|
-40.02
|
-47.67
|
-62.84
|
-60.42
|
-73.95
|
-58.21
|
-51.53
|
-65.17
|
-66.57
|
-68.43
|
-70.42
|
-76.4
|
Net income
1 |
-37.7
|
-41.38
|
-47.17
|
-40.37
|
-47.93
|
-63.23
|
-59.43
|
-73.94
|
-58.66
|
-51.42
|
-63.04
|
-65.28
|
-67.62
|
-70.35
|
-75.82
|
Net margin
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
EPS
2 |
-0.3500
|
-0.3600
|
-0.4100
|
-0.3500
|
-0.4100
|
-0.4900
|
-0.4600
|
-0.5700
|
-0.4500
|
-0.3600
|
-0.4370
|
-0.4450
|
-0.4550
|
-0.4762
|
-0.5062
|
Dividend per Share
2 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
11/5/21
|
2/4/22
|
6/8/22
|
8/5/22
|
11/4/22
|
2/3/23
|
5/22/23
|
8/10/23
|
11/9/23
|
2/12/24
|
-
|
-
|
-
|
-
|
-
|
Fiscal Period: March |
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net Debt
1 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Net Cash position
1 |
-
|
400
|
494
|
377
|
653
|
532
|
288
|
Leverage (Debt/EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Free Cash Flow
1 |
-53.4
|
-83.5
|
-106
|
-188
|
-211
|
-281
|
-274
|
ROE (net income / shareholders' equity)
|
-
|
-44.3%
|
-36.4%
|
-50.7%
|
-48.6%
|
-46.7%
|
-61%
|
ROA (Net income/ Total Assets)
|
-
|
-
|
-
|
-
|
-45.7%
|
-44.6%
|
-
|
Assets
1 |
-
|
-
|
-
|
-
|
546.2
|
618.1
|
-
|
Book Value Per Share
2 |
-
|
4.460
|
4.280
|
2.780
|
4.510
|
2.810
|
1.070
|
Cash Flow per Share
2 |
-
|
-0.9500
|
-0.9700
|
-1.530
|
-1.190
|
-0.2700
|
-
|
Capex
1 |
0.03
|
0.21
|
0.25
|
0.2
|
3.5
|
4.05
|
5.27
|
Capex / Sales
|
-
|
-
|
-
|
-
|
-
|
28.1%
|
10.06%
|
Announcement Date
|
6/29/20
|
6/1/21
|
6/8/22
|
5/22/23
|
-
|
-
|
-
|
Last Close Price
28.95
USD Average target price
50.43
USD Spread / Average Target +74.19% Consensus |
1st Jan change
|
Capi.
|
---|
| -31.28% | 4.21B | | +67.53% | 63.85B | | -0.77% | 41.83B | | +45.66% | 40.65B | | -10.72% | 27.12B | | +13.30% | 26.52B | | -22.79% | 18.69B | | +4.70% | 12.73B | | +24.10% | 12.11B | | +27.41% | 12.07B |
Other Biotechnology & Medical Research
|